Go to
JCI Insight
Derek J. Hausenloy, Derek M. Yellon
Citation Information: J Clin Invest. 2013;123(1):92-100. https://doi.org/10.1172/JCI62874.
Derek J. Hausenloy, Derek M. Yellon
Published January 2, 2013
Citation Information: J Clin Invest. 2013;123(1):92-100. https://doi.org/10.1172/JCI62874.
Abstract
Acute myocardial infarction (MI) is a major cause of death and disability worldwide. In patients with MI, the treatment of choice for reducing acute myocardial ischemic injury and limiting MI size is timely and effective myocardial reperfusion using either thombolytic therapy or primary percutaneous coronary intervention (PPCI). However, the process of reperfusion can itself induce cardiomyocyte death, known as myocardial reperfusion injury, for which there is still no effective therapy. A number of new therapeutic strategies currently under investigation for preventing myocardial reperfusion injury have the potential to improve clinical outcomes in patients with acute MI treated with PPCI.
Authors
Derek J. Hausenloy, Derek M. Yellon
Full Text PDF | Download (750.11 KB)
Follow JCI:
Copyright © 2020 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)
Copyright © 2020 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)